Rivfloza (nedosiran)

Indications for Prior Authorization

Rivfloza (nedosiran)
  • For diagnosis of Primary Hyperoxaluria Type 1 (PH1)
    Indicated to lower urinary oxalate levels in children 2 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function, e.g., eGFR ≥ 30 mL/min/1.73 m2.

Criteria

Rivfloza

Prior Authorization (Initial Authorization)

Length of Approval: 12 Month(s)

  • Diagnosis of primary hyperoxaluria type 1 (PH1)
  • AND
  • Disease has been confirmed by both of the following: [2]
    • One of the following:
      • Elevated urinary oxalate excretion
      • Elevated plasma oxalate concentration
      • Spot urinary oxalate to creatinine molar ratio greater than normal for age
      AND
    • One of the following:
      • Genetic testing demonstrating a mutation in the alanine:glyoxylate aminotransferase (AGXT) gene
      • Liver biopsy demonstrating absence or reduced alanine:glyoxylate aminotransferase (AGT) activity
    AND
  • Patient is 2 years of age or older [1]
  • AND
  • Patient has preserved kidney function ( e.g., eGFR greater than or equal to 30mL/min/1.73m^2)
  • AND
  • Patient has not received a liver transplant [A, 2]
  • AND
  • Prescribed by or in consultation with one of the following:
    • Hepatologist
    • Nephrologist
    • Urologist
    • Geneticist
    • Specialist with expertise in the treatment of PH1
Rivfloza

Prior Authorization (Reauthorization)

Length of Approval: 12 Month(s)

  • Patient demonstrates positive clinical response to therapy (e.g., decreased urinary oxalate excretion, decreased plasma oxalate concentration)
  • AND
  • Patient has not received a liver transplant
  • AND
  • Prescribed by or in consultation with one of the following:
    • Hepatologist
    • Nephrologist
    • Urologist
    • Geneticist
    • Specialist with expertise in the treatment of PH1
P & T Revisions

1970-01-01, 2025-02-17, 2024-02-20

  1. Rivfloza prescribing information. Pyramid Laboratories. Costa Mesa, CA. March 2025.
  2. UptoDate: Primary hyperoxaluria. Available at https://www.uptodate.com/contents/primary-hyperoxaluria?search=Primary%20Hyperoxaluria%20Type%201%20§ionRank=1&usage_type=default&anchor=H2111703101&source=machineLearning&selectedTitle=1%7E150&display_rank=1#H2111703101. Accessed April 13, 2025.

  1. Liver transplantation provides the definitive cure for PH type 1 by restoring the missing enzyme, which lowers oxalate production to the normal range. [2]

  • 2025-02-17: 2025 Annual Review.
  • 2024-02-20: New UM PA Criteria